Table 1.
Clinical Characteristics of European American Participants in the Diabetes Heart Study (n = 901)
| Mean ± SD or % (n) | Median (Range) | |
|---|---|---|
| Age (years) | 61.4 ± 9.5 | 61.4 (33.5–85.9) |
| Gender (% female) | 56.1 (505) | |
| BMI (kg/m2) | 31.8 ± 6.7 | 30.7 (16.6–58.0) |
| Diabetes diagnosis | 83.1 (749) | |
| Duration of diabetes (years) | 10.2 ± 7.0 | 8.0 (0–41.0) |
| Total cholesterol (mg/dL) | 189.0 ± 41.7 | 185.0 (74.0–350.0) |
| LDL cholesterol (mg/dL) | 105.9 ± 32.2 | 103.0 (14.0–230.0) |
| HDL cholesterol (mg/dL) | 43.7 ± 12.6 | 42.0 (18.0–90.0) |
| Triglycerides (mg/dL) | 207.3 ± 139.1 | 176.0 (30.0–1310) |
| Smoking | ||
| Current | 17.0 (152) | |
| Past | 41.4 (371) | |
| Never | 41.7 (374) | |
| Hypertension | 83.7 (754) | |
| Resting heart rate (beats/min) | 70.1 ± 12.3 | 69.0 (40.0–158.0) |
| QT interval duration (ms) | 394.0 ± 33.1 | 392.0 (270.0–564.0) |
| QTc interval duration (ms) | 421.9 ± 24.1 | 418.5 (332.6–536.1) |
| QT‐altering medications | ||
| Beta‐blockers | 27.6 (245) | |
| Calcium channel blockers | 18.5 (167) | |
| Class III antidysrhythmic drugs* | 0.44 (4) | |
*Class III antidysrhythmic drugs include dofetilide (n = 0), sotalol (n = 1), and amiodarone (n = 3).